Paola Ajdinaj

Dr. Paola Ajdinaj

Department of Neuroscience, Imaging and Clinical Sciences, Chieti, Italy
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
LFLaura Ferri
Laura Ferri
PAPaola Ajdinaj
Paola Ajdinaj
MRMarianna Gabriella Rispoli
Marianna Gabriella Rispoli
CCClaudia Carrarini
Claudia Carrarini
FBFilomena Barbone
Filomena Barbone
Laura BonanniLaura Bonanni
Laura Bonanni
Background: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disorder which affects the motor neurons. Growing evidence suggests that ALS may impact the metabolic system, including the glucose metabolism. Several studies investigated the role of Diabetes Mellitus (DM) as risk and/or prognostic factor. However, a clear correlation between DM and ALS has not been defined. In this review, we focus on the role of DM in ALS, examining the different hypotheses on how perturbations of glucose metabolism may interact with the pathophysiology and the course of ALS. Methods: We undertook an independent PubMed literature search, using the following search terms: ((ALS) OR (Amyotrophic Lateral Sclerosis) OR (Motor Neuron Disease)) AND ((Diabetes) OR (Glucose Intolerance) OR (Hyperglycemia)). Review and original articles were considered. Results: DM appears not to affect ALS severity, progression, and survival. Contrasting data suggested a protective role of DM on the occurrence of ALS in elderly and an opposite effect in younger subjects. Conclusions: The actual clinical and pathophysiological correlation between DM and ALS is unclear. Large longitudinal prospective studies are needed. Achieving large sample sizes comparable to those of common complex diseases like DM is a challenge for a rare disease like ALS. Collaborative efforts could overcome this specific issue.

12 January 2023 in Neurological Sciences
Verified
Journal Article
Open access
PDF file
MDMaria D'Apolito
Maria D'Apolito
MRMarianna Gabriella Rispoli
Marianna Gabriella Rispoli
PAPaola Ajdinaj
Paola Ajdinaj
ADAnna Digiovanni
Anna Digiovanni
VTValentina Tomassini
Valentina Tomassini
GLGiovanna De Luca
Giovanna De Luca

16 October 2022 in Brain Sciences
Verified
Journal Article
Open access
PDF file
SISalvatore Iacono
Salvatore Iacono
Vincenzo Di StefanoVincenzo Di Stefano
Vincenzo Di Stefano
PAPaolo Alonge
Paolo Alonge
Claudia VinciguerraClaudia Vinciguerra
Claudia Vinciguerra
GMGiammarco Milella
Giammarco Milella
Filippo BrighinaFilippo Brighina
Filippo Brighina
Background: The safety of the new vaccines against SARS-CoV-2 have already been shown, although data on patients with polyneuropathy are still lacking. The aim of this study is to evaluate the adherence to SARS-CoV-2 vaccination, as well as the reactogenicity to those vaccines in patients affected by neuropathy. Methods: A multicentric and web-based cross-sectional survey was conducted among patients affected by neuropathy from part of South Italy. Results: Out of 285 responders, n = 268 were included in the final analysis and n = 258 of them (96.3%) were fully vaccinated. Adherence to vaccination was higher in patients with hereditary neuropathies compared to others, while it was lower in patients with anti-MAG neuropathy (all p < 0.05). The overall prevalence of adverse events (AEs) was 61.2% and its occurrence was not associated with neuropathy type. Being female and of younger age were factors associated with higher risk of AEs, while having an inflammatory neuropathy and steroids assumption were associated with a lower risk (all p < 0.05). Younger age, having had an AE, and COVID-19 before vaccination were factors associated with symptoms worsening after vaccination (all p < 0.05). (4) Conclusions: Patients with neuropathy showed a high level of adherence to COVID-19 vaccination. Safety of vaccines in patients with neuropathies was comparable to the general population and it was more favorable in those with inflammatory neuropathy.

7 October 2025 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PAPaola Ajdinaj
Paola Ajdinaj
NMNeus Mongay-Ochoa
Neus Mongay-Ochoa
MAManel Alberich
Manel Alberich
Mar TintoréMar Tintoré
Mar Tintoré
XMXavier Montalban
Xavier Montalban
JSJaume Sastre-Garriga
Jaume Sastre-Garriga
Background: This study aimed to test the association between cervical canal area (CCaA), a proxy for spinal cord reserve, measured at the first demyelinating event and disability accumulation in people with multiple sclerosis (pwMS). Methods: Subjects with a clinically isolated syndrome (CIS) enrolled at Cemcat between January 2009 and December 2014 were included if they had a baseline brain three-dimensional T1-weighted image (3DT1WI), at least a 10-year clinical follow-up, and diagnosis of MS during follow-up. Clinical data were collected at the onset of CIS, and at 6 months, 1 year, 5 years, 10 years, and at the last follow-up visit. CCaA was measured on 3DT1WI using a validated segmentation pipeline at the C2/C3 and C3/C4 disc levels. Results: Of the initial 121 pwMS, the final cohort comprised 81 pwMS with CCaA measures at C2/C3 and 76 pwMS at C3/C4. Linear mixed-effects models showed that while CCaA was not predictive of Expanded Disability Status Scale (EDSS) at disease onset, its influence on disability accumulation increased over time (C3/C4: CCaA-Time interaction, β = −0.023, p = 0.034). Conclusion: Larger spinal cord reserve at disease onset appeared to be associated with a slower rate of disability accumulation, supporting the concept of spinal cord reserve.

31 July 2021 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
MRMarianna Gabriella Rispoli
Marianna Gabriella Rispoli
LFLaura Ferri
Laura Ferri
PAPaola Ajdinaj
Paola Ajdinaj
VFValeriana Falzano
Valeriana Falzano
AMAntonio Di Muzio
Antonio Di Muzio

8 December 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MOMarco Onofrj
Marco Onofrj
MRMatteo Alessandro De Rosa
Matteo Alessandro De Rosa
MRMirella Russo
Mirella Russo
PAPaola Ajdinaj
Paola Ajdinaj
DCDario Calisi
Dario Calisi
SSStefano L. Sensi
Stefano L. Sensi
Parkinson’s Disease (PD) is a multifaceted neurodegenerative disorder characterized, in addition to the well-recognized motor disturbances, by a complex interplay between cognitive and psychiatric manifestations. We dissect the complex landscape of PD-related psychiatric symptoms, taking into account the impact of functional neurological disorders, somatic delusions, impulse control disorders, and conditions within the bipolar spectrum. The newer entities of somatoform and functional neurological disorders, as well as preexisting bipolar spectrum disorders, are analyzed in detail. Moreover, we emphasize the need for a holistic understanding of PD, wherein the cognitive and psychiatric dimensions are valued alongside motor symptoms. Such an approach aims to facilitate early detection and personalized interventions, and enhance the overall quality of life for individuals suffering from this neurodegenerative disorder.